Risk and Volatility
Orgenesis has a beta of 3.06, meaning that its share price is 206% more volatile than the S&P 500. Comparatively, Virios Therapeutics has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500.
Profitability
This table compares Orgenesis and Virios Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Orgenesis | -3,827.81% | N/A | -130.18% |
| Virios Therapeutics | N/A | -130.33% | -115.00% |
Insider & Institutional Ownership
22.6% of Orgenesis shares are owned by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are owned by institutional investors. 1.9% of Orgenesis shares are owned by insiders. Comparatively, 12.2% of Virios Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Orgenesis | $662,000.00 | 0.01 | -$55.36 million | ($11.51) | 0.00 |
| Virios Therapeutics | N/A | N/A | -$5.30 million | ($0.27) | -6.26 |
Virios Therapeutics has lower revenue, but higher earnings than Orgenesis. Virios Therapeutics is trading at a lower price-to-earnings ratio than Orgenesis, indicating that it is currently the more affordable of the two stocks.
About Orgenesis
Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.
About Virios Therapeutics
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.
Receive News & Ratings for Orgenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orgenesis and related companies with MarketBeat.com's FREE daily email newsletter.
